Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes

N/AUnknownNCT02072551

Assistance Publique - Hôpitaux de Paris17 enrolled

Overview

The main objective of this study is to evaluate Beta cells in patients with a neonotal diabetes linked to a genetic abnormality Metabolic caracteristics will described using a transversal cohort study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age : 18 à 65 year * diabetic patient with a neonatal diabetis (before 1 year old) and need for insuline or patient with a relative having neonatal diabetis Exclusion Criteria: Diabète induit (médicaments - ex corticoïdes) ou syndromique * infection * cancer * pegnancy

Locations (1)

Hopital Siant-louis

Paris, France

Outcomes

Primary Outcomes

Mean insulin secretion output

Time frame: Week after inclusion

Secondary Outcomes

insulin secretion outout after arginine perfusion

Time frame: during hospitalisation (3 days)

sensitivity to insulin

Time frame: during hospitalisation (3 days)

glucago secretion output

Time frame: during hospitalisation (3 days)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.